UnknownNot Applicable

Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients

China500 participantsStarted 2021-04-01

Plain-language summary

The investigator's purpose is to study the pharmacokinetics and pharmacodynamics of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc in elderly ICU patients and recommend an individual dosage regimen of those antibiotics.

Who can participate

Age range65 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * (1) Age ≥65 years old; (2) According to the doctor's advice, use biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc for anti-infection treatment; Exclusion Criteria: * (1) Patients who are expected to die within 48 hours; (2) Patients with allergic to β-lactam antibiotics, Carbapenems, Ticacycline and Levofloxacin.etc drugs; (3) Patients receiving other investigational drugs; (4) Other factors that the researcher considers unsuitable for inclusion.

What they're measuring

The peak plasma drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc

Timeframe: at (5-10) minutes after intravenous administration

The random plasma drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc

Timeframe: at (0.5-10) hours after intravenous administration

The trough plasma drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc

Timeframe: at 1-2 hours before the next administration

Trial details

NCT IDNCT04799626

SponsorShandong University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-30

Contact for this trial

Wei Zhao, Ph.D

053188383308 zhao4wei2@hotmail.com

View on ClinicalTrials.gov More Elderly Infection trials